Planet Briefing

First published · Last updated

MA07.09 Three-Year Survival Update and Biomarker Analysis of Neoadjuvant Chemoimmunotherapy in Potentially Resectable Stage IIIA/IIIB NSCLC

A journal article reporting a three-year survival update and biomarker analysis for neoadjuvant chemoimmunotherapy in potentially resectable Stage IIIA/IIIB non-small cell lung cancer. The content is published as a journal article by Elsevier BV on 2025-10-01.

Endobronchial radiation therapy for non-small cell lung cancer. AP view
Illustrative image: Endobronchial radiation therapy for non-small cell lung cancer. AP view — Tdvorak/Wikimedia Commons, CC BY-SA 4.0

Categories: public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence
5/10
Geographic reach
2/10
Global importance
3/10
Impact magnitude
4/10
Positivity
5/10
Urgency
2/10

Why it matters

The article provides multi-year survival and biomarker data relevant to treatment of Stage IIIA/IIIB NSCLC.

Sources

Report an issue